PDF(Pubmed)
Abstract：
BACKGROUND: Protein induced by vitamin K absence II (PIVKA-II) is an abnormal prothrombin increased in gastrointestinal malignancy. We aimed to evaluate PIVKA-II in comparison to established pancreatic cancer (PC) biomarkers (CA 19-9, carcinoembryonic antigen (CEA) and CA 242) measured in PC patients and in patients with benign pancreatic diseases.
METHODS: We studied 26 PC patients (Group 1) and 20 patients with benign pancreatic diseases (Group 2). PIVKA-II and CEA were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Gent, Belgium), CA 19-9 and CA 242 were measured by ELSA (CisBio Bioassays, Codolet, France) and EIA (Fujirebio Diagnostics AB, Göteborg, Sweden), respectively. Receiver operating characteristic (ROC) analysis was performed to assess biomarkers\' diagnostic characteristics in both groups.
RESULTS: Median and interquartile range (IQR) in Group 1 and Group 2 were: 1749.0 (320.2 - 3921.0) vs. 31.0 (23.0 - 43.0) mAU/mL (P < 0.001) for PIVKA-II, 260.0 (158.7 - 272.0) vs. 45.2 (9.0 - 58.0) U/mL (P = 0.034) for CA 19-9, 104.0 (30.2 - 150.0) vs. 7.2 (4.8 - 26.0) U/mL (P < 0.050) for CA 242, 9.4 (5.3 - 37.5) vs. 4.5 (1.8 - 7.0) ng/mL (P = 0.021) for CEA. Areas under the ROC curve of PIVKA-II, CA 19-9, CA 242, CEA were 0.86 (95% CI: 0.71 - 1.00), 0.58 (95% CI: 0.38 - 0.78), 0.73 (95% CI: 0.54 - 0.92), 0.64 (95% CI: 0.44 - 0.85), respectively.
CONCLUSIONS: PIVKA-II is significantly higher in PC than in benign pancreatic diseases. PIVKA-II shows a rather good diagnostic performance compared to CA 19-9, CEA and CA242, thus its determination could help PC management.
METHODS: We studied 26 PC patients (Group 1) and 20 patients with benign pancreatic diseases (Group 2). PIVKA-II and CEA were measured by chemiluminescent enzyme immunoassay method (CLEIA) on LUMIPULSE G1200 (Fujirebio-Europe, Gent, Belgium), CA 19-9 and CA 242 were measured by ELSA (CisBio Bioassays, Codolet, France) and EIA (Fujirebio Diagnostics AB, Göteborg, Sweden), respectively. Receiver operating characteristic (ROC) analysis was performed to assess biomarkers\' diagnostic characteristics in both groups.
RESULTS: Median and interquartile range (IQR) in Group 1 and Group 2 were: 1749.0 (320.2 - 3921.0) vs. 31.0 (23.0 - 43.0) mAU/mL (P < 0.001) for PIVKA-II, 260.0 (158.7 - 272.0) vs. 45.2 (9.0 - 58.0) U/mL (P = 0.034) for CA 19-9, 104.0 (30.2 - 150.0) vs. 7.2 (4.8 - 26.0) U/mL (P < 0.050) for CA 242, 9.4 (5.3 - 37.5) vs. 4.5 (1.8 - 7.0) ng/mL (P = 0.021) for CEA. Areas under the ROC curve of PIVKA-II, CA 19-9, CA 242, CEA were 0.86 (95% CI: 0.71 - 1.00), 0.58 (95% CI: 0.38 - 0.78), 0.73 (95% CI: 0.54 - 0.92), 0.64 (95% CI: 0.44 - 0.85), respectively.
CONCLUSIONS: PIVKA-II is significantly higher in PC than in benign pancreatic diseases. PIVKA-II shows a rather good diagnostic performance compared to CA 19-9, CEA and CA242, thus its determination could help PC management.
摘要：
背景：维生素K缺乏诱导的蛋白质II（PIVKA-II）是胃肠道恶性肿瘤中异常增加的凝血酶原。我们旨在与在PC患者和良性胰腺疾病患者中测量的已建立的胰腺癌（PC）生物标志物（CA19-9，癌胚抗原（CEA）和CA242）进行比较，评估PIVKA-II。
方法：我们研究了26例PC患者（第1组）和20例胰腺良性疾病患者（第2组）。PIVKA-II和CEA通过化学发光酶免疫分析法（CLEIA）在LUMIPULSEG1200（Fujirebio-Europe，Gent,比利时),CA19-9和CA242由ELSA测量(CisBio生物测定，Codolet,法国）和EIA（Fujirebio诊断AB，哥德堡,瑞典),分别。进行受试者工作特征（ROC）分析以评估两组的生物标志物诊断特征。
结果：第1组和第2组的中位数和四分位数范围（IQR）分别为：1749.0（320.2-3921.0）与PIVKA-II为31.0（23.0-43.0）mAU/mL（P<0.001），260.0（158.7-272.0）与对于CA19-9，45.2（9.0-58.0）U/mL（P=0.034），104.0（30.2-150.0）与CA242的7.2（4.8-26.0）U/mL（P<0.050），9.4（5.3-37.5）与CEA为4.5（1.8-7.0）ng/mL（P=0.021）。PIVKA-II的ROC曲线下面积,CA19-9，CA242，CEA为0.86（95%CI：0.71-1.00），0.58（95%CI：0.38-0.78），0.73（95%CI：0.54-0.92），0.64（95%CI：0.44-0.85），分别。
结论：PIVKA-II在PC中明显高于良性胰腺疾病。与CA19-9、CEA和CA242相比,PIVKA-II显示出相当好的诊断性能,因此其确定可以帮助PC管理。
方法：我们研究了26例PC患者（第1组）和20例胰腺良性疾病患者（第2组）。PIVKA-II和CEA通过化学发光酶免疫分析法（CLEIA）在LUMIPULSEG1200（Fujirebio-Europe，Gent,比利时),CA19-9和CA242由ELSA测量(CisBio生物测定，Codolet,法国）和EIA（Fujirebio诊断AB，哥德堡,瑞典),分别。进行受试者工作特征（ROC）分析以评估两组的生物标志物诊断特征。
结果：第1组和第2组的中位数和四分位数范围（IQR）分别为：1749.0（320.2-3921.0）与PIVKA-II为31.0（23.0-43.0）mAU/mL（P<0.001），260.0（158.7-272.0）与对于CA19-9，45.2（9.0-58.0）U/mL（P=0.034），104.0（30.2-150.0）与CA242的7.2（4.8-26.0）U/mL（P<0.050），9.4（5.3-37.5）与CEA为4.5（1.8-7.0）ng/mL（P=0.021）。PIVKA-II的ROC曲线下面积,CA19-9，CA242，CEA为0.86（95%CI：0.71-1.00），0.58（95%CI：0.38-0.78），0.73（95%CI：0.54-0.92），0.64（95%CI：0.44-0.85），分别。
结论：PIVKA-II在PC中明显高于良性胰腺疾病。与CA19-9、CEA和CA242相比,PIVKA-II显示出相当好的诊断性能,因此其确定可以帮助PC管理。
